Predictive Oncology Inc Stock News

Predictive Oncology Inc. ( POAI ) Q3 2025 Earnings Call November 17, 2025 9:00 AM EST Company Participants Raymond Vennare - CEO & Chairman Joshua Blacher - Interim Chief Financial Officer Thomas McLaughlin Kyle Okamoto Presentation Operator Before we begin, let me quickly remind you that during the course of this presentation, the company will make forward-looking statements. We caution you th...

PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlig...

Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors

Investment creates the world's first Strategic Compute Reserve  Strategy complements Predictive Oncology's AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (“Predictive Oncology” or the “Company”) (Nasdaq: POAI) today announced the closing of two previously announced private investment in public equity transactions (“P...

Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements

Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025 Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025

Collaboration builds upon positive results utilizing Predictive Oncology's AI platform to identify new indications for existing drugs Collaboration builds upon positive results utilizing Predictive Oncology's AI platform to identify new indications for existing drugs

NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a new...